Cradle builds generative-AI software that lets protein engineers specify a desired property — thermostability, expression yield, binding affinity, pH tolerance — and receive sequence variants predicted to improve it, replacing the trial-and-error rounds that dominate conventional directed evolution. The models are trained on public sequence data and on proprietary datasets generated in Cradle's own wet lab, which exists specifically to produce the experimental feedback the models need across additional protein modalities. Customers report 1.2x to 12x reductions in R&D cycles across therapeutics, diagnostics, agriculture, chemicals and food, and the company's enzyme models placed at or near the top among thirty industry and academic teams in the Align to Innovate competition. Founded in 2021 by Stef van Grieken (CEO, ex-Google) and Jelle Prins, Cradle has raised over $100M including a $73M Series B led by IVP, and works with Novo Nordisk, Johnson & Johnson, Novonesis, Grifols and Ginkgo Bioworks.